ArticleScientific reports2025
STAU1 exhibits oncogenic characteristics and modulates alternative splicing and gene expression in lung adenocarcinoma cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Staufen double-stranded RNA-binding protein 1 (STAU1) plays a significant role in cancer development and is associated with survival outcomes in patients with lung cancer. However, its specific functions and molecular mechanisms in lung adenocarcinoma (LUAD) remain underexplored. We conducted a comprehensive analysis of the role and mechanism of STAU1 in A549 cells via RNA sequencing (RNA-seq) and in vitro experiments. STAU1 is highly expressed in A549 cells, and the proliferation, invasion, and migration capabilities of siSTAU1 cells are markedly inhibited, while the level of apoptosis is increased. Through RNA-seq analysis, we identified 197 differentially expressed genes (DEGs) and 1,362 STAU1-regulated alternative splicing events (ASEs). The DEGs were specifically enriched in cell adhesion pathways, whereas the ASE genes were predominantly associated with cell division and the cell cycle. Furthermore, we validated the expression of several genes related to proliferation, invasion, and migration, as well as the AS patterns. Specifically, the expression levels of CFHR1, KLF2, and RHOB were upregulated in the siSTAU1 samples, whereas the expression of MASTL and STC2 was downregulated. Additionally, the AS patterns of BIN1 and SNHG17 were abnormal, which was corroborated by PCR experiments. Our study suggests that STAU1 has oncogenic characteristics and may modulate these genes to influence the proliferation, invasion, and migration of lung adenocarcinoma cells. This research offers new insights that may contribute to the diagnosis and treatment of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.